No abstract available
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adrenergic beta-Antagonists / adverse effects
-
Adrenergic beta-Antagonists / pharmacology
-
Adrenergic beta-Antagonists / therapeutic use
-
Aged
-
Angiotensin II Type 1 Receptor Blockers / adverse effects
-
Angiotensin II Type 1 Receptor Blockers / pharmacology
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / adverse effects
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Antihypertensive Agents / adverse effects
-
Antihypertensive Agents / classification
-
Antihypertensive Agents / pharmacology
-
Antihypertensive Agents / therapeutic use*
-
Blood Pressure / drug effects*
-
Calcium Channel Blockers / adverse effects
-
Calcium Channel Blockers / pharmacology
-
Calcium Channel Blockers / therapeutic use
-
Case Management
-
Clinical Trials as Topic
-
Cohort Studies
-
Coronary Disease / prevention & control
-
Diabetes Mellitus, Type 2 / etiology
-
Diuretics / adverse effects
-
Diuretics / pharmacology
-
Diuretics / therapeutic use
-
Double-Blind Method
-
Humans
-
Hypertension / drug therapy*
-
Meta-Analysis as Topic
-
Middle Aged
-
Proportional Hazards Models
-
Renin-Angiotensin System / drug effects
-
Risk
-
Risk Reduction Behavior
-
Treatment Outcome
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin II Type 1 Receptor Blockers
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents
-
Calcium Channel Blockers
-
Diuretics